Immortal Dragons Propels the Future of Tissue Engineering with Strategic Investment in Frontier Bio

August 19, 2025 - Singapore - Immortal Dragons, the $40 million purpose-driven longevity fund, today announced a landmark investment in Frontier Bio, a company at the absolute cutting edge of regenerative medicine. This strategic partnership catapults Frontier Bio’s revolutionary 3D biofabrication and tissue engineering platform to the forefront of the fight against age-related organ failure. The investment is a powerful testament to Immortal Dragons' visionary strategy of backing technologies that can fundamentally rewrite the narrative of human aging.

Frontier Bio is tackling one of the most critical challenges in modern medicine: the failure of synthetic vascular grafts, which suffer from failure rates as high as 65% and plague a market valued at over $12 billion. The company’s suite of technologies, encompassing advanced 3D biofabrication, stem cell science, and sophisticated organ-on-a-chip systems, is creating a new generation of functional, living tissues. Their bio-engineered blood vessels have demonstrated flawless performance, showing a complete absence of thrombosis (blood clotting), robust cell integration, and seamless fusion with surrounding tissue—a monumental leap beyond current synthetic options.

A Revolution in Regenerative Medicine

At the vanguard of this revolution is Frontier Bio's pioneering work in creating tissue-engineered blood vessels that eliminate the risk of thrombosis. In rigorous large animal studies, the company's vascular grafts have shown extraordinary success, remaining fully functional and integrating perfectly without any signs of clotting or infection. These grafts, seeded with stem cells, become living parts of the body, a feat that synthetic materials cannot replicate.

This breakthrough technology offers a powerful combination of advantages: off-the-shelf availability, suitability for small and complex blood vessels, and immediate cellularization upon implant. This positions Frontier Bio’s solution as vastly superior to both autologous vessels, which are limited in supply, and existing synthetic grafts, which perform poorly.

"Refreshing to meet investors fluent in the field, technology, and related domains. Immortal Dragons acted on insight, not hype," said Eric Bennett, CEO of Frontier Bio.

A Masterstroke in Strategic Alignment

This investment is a masterstroke in Immortal Dragons’ grand strategy to conquer organ failure, the leading cause of death for individuals over 65. By championing Frontier Bio’s scalable biofabrication technology, Immortal Dragons is not only addressing the staggering $150 billion organ transplant market but also advancing its core thesis: that aging-related deaths can be rendered obsolete through replacement technology.

Today, countless patients languish on organ transplant waiting lists, a tragic reality born from a severe shortage of donor organs. Frontier Bio’s platform has the potential to eradicate these bottlenecks by manufacturing organs on-demand from a patient’s own cells, thereby eliminating rejection risk and wait times.

Boyang Wang, founder of Immortal Dragons, explained: "3D Biofabrication represents a critical piece of replacement technologies, having the ability to manufacture specific organs and tissues on-demand provides the foundational infrastructure that makes biological part replacement possible."

Building an Ecosystem of Longevity Solutions

Frontier Bio’s capabilities will create powerful synergies across the entire Immortal Dragons portfolio. The company’s organ printing technology provides the essential manufacturing backbone for whole-body replacement initiatives, while its tissue engineering expertise can support the development of artificial wombs by creating the complex vascular networks required for such systems. This investment is a key component in building a comprehensive ecosystem of mutually reinforcing longevity solutions.

This forward-thinking vision is earning accolades from top minds in the field. As Brian Kennedy, a distinguished professor and prominent longevity leader at the National University of Singapore, notes: “Immortal Dragons is making thoughtful, mission-driven investments in longevity by supporting high-impact science with long-term potential."

About Immortal Dragons:

Immortal Dragons (https://www.id.life/) is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders' talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.

For Press Inquiries:
Boyang Wang
Founder, Immortal Dragons
press@id.life